Navigation Links
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
Date:3/19/2013

NEW YORK, March 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Financial Assessment of the Global Pharmaceutical and Biotechnology Industry 
http://www.reportlinker.com/p01120885/Financial-Assessment-of-the-Global-Pharmaceutical-and-Biotechnology-Industry .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Financial Management is the Key Strategy for Sustainability

This financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718 publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each industry are also highlighted.

The Key Issues/Challenges Faced by Industry Participants in the Pharmaceutical and Biotechnology Industry Include:

•The global economic slowdown
•Regulatory compliance
•Reducing profitability
•Increasing R&D costs
•Pricing pressures
•Counterfeit business

Financial Analysis of the Pharmaceutical and Biotechnology Industry

1. Margin Analysis
•The pharmaceutical industry has generally witnessed smaller margins due to increasing competition from generics, pricing pressures, and decreasing healthcare spending.
•In the biotechnology industry, companies within low revenue range and relatively new products have witnessed negative margins because of the heavy investment in R&D and SG&A (selling and general expenses).

2. Profitability Analysis
•Companies with a large portfolio of drugs have seen higher profitability in the pharmaceutical industry.
•The long timelines and accumulating expenditures incurred before a drug is commercialized is making the biotechnology industry less profitable in initial years, even resulting in negative margins for companies that are smaller in terms of revenue.

3. Turnover Analysis
•In both the pharmaceutical and biotechnology industries, companies with lower revenue had poor turnover ratios because of the huge investments made in assets and in the development of the product.

4. Cash Reserve Analysis
•In the pharmaceutical industry the smaller companies in terms of revenue are increasing their cash reserve as a percentage of their assets.
•In the biotechnology industry, both small and large companies in terms of revenue are increasing their cash reserve as a percentage of their assets.

5. R&D to Sales Ratio
•Both the pharmaceutical and biotechnology industries did not witness a great variation in the R&D to sales ratio in 2011 compared to the previous year. Though there was a general decline in the overall sales in both the pharmaceutical and biotechnology industries, the R&D expenses were not considerably reduced.

Who Will Benefit?

•Pharmaceutical & biotechnology companies
•Private equity
•Venture capital investors
•Fund managers
•Retail investors
•Sovereign wealth funds
•Hedge funds
•Insurance funds and other members of the investing community

Table Of Contents

1. Executive Summary

2. Definition of Key Terms

3. Research Objective and Scope

4. Research Methodology

5. Key Issues/Challenges Faced by Industry Participants

6. Pharmaceutical Industry

7. Top Performers in the Pharmaceutical Industry

8. Biotechnology Industry

9. Top Performers in the Biotechnology Industry

10. The Frost & Sullivan Story

To order this report:
Pharmaceutical Industry: Financial Assessment of the Global Pharmaceutical and Biotechnology Industry 

__________________________
Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
2. Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
3. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
4. Organovo Reports 2012 Financial Results
5. Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
6. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
7. China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012
8. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
9. Discovery Labs Reports Fourth Quarter 2012 Financial Results
10. GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2012
11. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology:
(Date:4/26/2017)... DC (PRWEB) , ... April ... ... Association (ATA) is thrilled to announce the ATA 2017 President’s Awards recipients, ... innovation and demonstrated superior healthcare delivery. , The ATA 2017 President’s ...
(Date:4/26/2017)... ... , ... Infertility may be a result of an underlying ... women become pregnant upon treating their diagnosis. , To properly diagnose ... We can provide the necessary information to diagnose and treat your problem. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
(Date:4/25/2017)... ... ... Lake Park Dental is now accepting new patients with crooked teeth who ... the help of this highly-effective, yet convenient system, patients can straighten their teeth and ... pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, of ...
Breaking Medicine News(10 mins):